Anavex Life Sciences (AVXL) Common Equity (2010 - 2025)

Anavex Life Sciences (AVXL) has 16 years of Common Equity data on file, last reported at $126.6 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 14.16% year-over-year to $126.6 million; the trailing twelve-month figure through Dec 2025 stood at $126.6 million (up 14.16% YoY), and the FY2025 full-year result was $94.9 million, down 21.12% from the prior year.
• Common Equity grew to $126.6 million in Q4 2025, from $94.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $157.1 million in Q2 2021 to a low of $75.8 million in Q1 2021.
• A 5-year average of $129.4 million and a median of $135.3 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 536.71% in 2021 and declined 29.91% in 2025, its largest moves.
• Tracing AVXL's Common Equity over 5 years: stood at $146.4 million in 2021, then fell by 7.68% to $135.1 million in 2022, then increased by 0.33% to $135.6 million in 2023, then fell by 18.19% to $110.9 million in 2024, then advanced by 14.16% to $126.6 million in 2025.
• Business Quant data shows AVXL's Common Equity at $126.6 million in Q4 2025, $94.9 million in Q3 2025, and $91.0 million in Q2 2025.